By otakuyassine3@gmail.com 
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Vertex Pharmaceuticals in a report released on Wednesday, February 19th. Cantor Fitzgerald analyst O. Brayer anticipates that the pharmaceutical company will post earnings of $16.12 per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $480.00 price objective on the stock. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last announced its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%.
A number of other equities analysts have also recently issued reports on the stock. Royal Bank of Canada upped their price target on shares of Vertex Pharmaceuticals from $407.00 to $408.00 and gave the stock a “sector perform” rating in a research note on Thursday. Bank of America dropped their price target on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating on the stock in a research note on Thursday, December 19th. UBS Group upped their price target on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Jefferies Financial Group upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price target for the stock from $500.00 to $550.00 in a research note on Monday, December 9th. Finally, Morgan Stanley upped their price target on Vertex Pharmaceuticals from $450.00 to $459.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 11th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $506.70.
Check Out Our Latest Stock Report on VRTX
Vertex Pharmaceuticals Stock Performance
Shares of VRTX stock opened at $484.24 on Friday. Vertex Pharmaceuticals has a 12 month low of $377.85 and a 12 month high of $519.88. The stock has a market cap of $124.35 billion, a PE ratio of -220.11, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. The company’s fifty day moving average price is $436.05 and its 200-day moving average price is $460.61.
Insider Activity
In related news, EVP Ourania Tatsis sold 310 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total transaction of $142,547.30. Following the sale, the executive vice president now owns 64,021 shares of the company’s stock, valued at $29,438,776.43. This trade represents a 0.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.20% of the company’s stock.
Institutional Investors Weigh In On Vertex Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in VRTX. Norges Bank bought a new stake in Vertex Pharmaceuticals during the fourth quarter valued at about $1,374,948,000. Parnassus Investments LLC acquired a new stake in Vertex Pharmaceuticals in the fourth quarter worth about $731,283,000. Edgewood Management LLC boosted its holdings in Vertex Pharmaceuticals by 7,876.3% in the third quarter. Edgewood Management LLC now owns 1,546,370 shares of the pharmaceutical company’s stock worth $719,186,000 after acquiring an additional 1,526,983 shares in the last quarter. Capital World Investors boosted its holdings in Vertex Pharmaceuticals by 5.7% in the fourth quarter. Capital World Investors now owns 28,325,695 shares of the pharmaceutical company’s stock worth $11,406,667,000 after acquiring an additional 1,514,993 shares in the last quarter. Finally, Capital Research Global Investors boosted its holdings in Vertex Pharmaceuticals by 15.8% in the fourth quarter. Capital Research Global Investors now owns 10,428,951 shares of the pharmaceutical company’s stock worth $4,199,713,000 after acquiring an additional 1,426,746 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Further Reading
Receive News & Ratings for Vertex Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.